Genmab — November 2025

[E_L]

GEN1059 and GEN1042 still in the Biontech pipeline at Q3 25...

[E_L]

ASH 2025 . enjoy.
https://submit.hematology.org/program?query=epcoritamab&is_sponsored=0&is_highlighted=0&is_on_demand=0&streaming_allowed=0&filterbox=false&legendbox=false&timezone=false&day=2025-12-05&pre_filter=All&viewType=list&segment=presentations&segmentname=Presentations&upcoming=0&order=starts_at

[E_L]

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting https://ir.genmab.com/news-releases/news-release-details/genmab-showcase-latest-blood-cancer-treatment-advancements-2025

[Plimsoller]

That's a long list E L Any chance of a late breaking abstract?

[Solsen]

7 orale præsentationer er flot. Biontech afholder en R&D update den 11. november, som kan være interessant som Genmab investor.

[E_L]

was this still not enough Plimsoller??? there is always a chance, but only very few LBA's , i think last year only 6 or so

[E_L]

i think the FL abstracts are important, in combination with the potential FDA approval late this month

[Plimsoller]

More wants more

[Plimsoller]

Thank you

[E_L]

[E_L]

the FDA reversed its previous position on a sBLA for UniQure and the stock drops 56%. not sure if that is what drives biotech sentiment this US morning but not a good bio-start for november...

[lahn1]

Er det bare mig eller bliver real world data på Epco og Glofi udlagt negativt. Man kan jo ikke sammenligne trials hvor pts skal være CD20 +ve med real world data i 3L hvor 80% af pts har tabt CD20 expression. Nogen som har et bud på om dette vil ændre peak sales på Epco ? Søg på Epcoritamab på X og jeg syntes budskabet er epco/Glofi præsterer dårligere i real life end i trials.

[npo]

My two cents : Whereas writer – and I trust other investors - appreciate in-put with a technical background from professionals in this forum. Regrettably, however, due to use of acronyms and abbreviations in-put often becomes so technical it often comes across gobbledygook – incomprehensible to ordinary mortals (investors). Use of “simpler” terms and less acronyms etc. could enable/attract more investors to read and follow progress and in the process be attracted to support Genmab.

[Bella1]

Tak, npo

[SEACOP]

Jeg nyder det høje niveau i dette forum, hvor jeg lærer meget. Det, som jeg ikke forstår, springer jeg nemt over. For mig findes kun dette sted, hvis jeg vil have god indsigt. Fortsæt venligst. Tak.

[lahn1]

Det koster blod, sved og tåre at være investeret i biotech. Jeg har sprugt meget i flere år Skriv en liste på alle de forkortelser og akronymer du har mødt, så er jeg sikker på de profesionelle her på PI er villige til at forklare. Det er min erfaring.

[E_L]

Pfizer Q3 2025 Tivdak $37mn , YTD $115mn . Now i don't know if this is the full number, as somewhere this year Genmab would assume more responsibilities for Tivdak / leading commercialization in Europe , so not sure who books what at the moment...

[Helge_LarsenPI-redaktør]

Knock-Your-Socks-Off-News – November 2025 https://www.linkedin.com/pulse/knock-your-socks-off-news-november-2025-genmab-vy0ze/

[E_L]

TEPEZZA
(teprotumumab-trbw) sales increased 15% year-over-year to $560 million in the third quarter, driven by higher inventory levels and higher net selling price https://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-2025-financial-results

[lahn1]

Har ikke noteret mig salget fra jnj og de øvrige partnere helt næøjagtigt, men vi ligger vel til en opjustering